An Oxford based company tries to use artificial intelligence to conceive more efficient vaccines


An Oxford based start-up, , tries to prove that artificial intelligence could help developing more efficient vaccines. They developed an algorithm-based system capable of creating antigens containing all the parts of the pathogen. In other words, this could help producing the next generation of „universal” vaccines that protect against future variants that could evolve in several major diseases. “Our prediction algorithm addresses all of these challenges, accelerating the creation of vaccines that are as good as they possibly can be and will stand up to whatever variants may come in the future,” co-founder and software engineer Phillip Kemlo declared. Genomic, epidemiological, immunological, clinical and evolutionary data are used to create models of antigens capable of responding to a particular pathogen in its current form as well as likely variants that may arise in the future.


The team were recently awarded £3.5m in funding in an investment round led by Hoxton Ventures and including early investors Creator Fund. Covid and malaria are targeted as candidates of developing researches. „Using this approach we are able to tackle emerging and challenging pathogens that had been failed by traditional approaches,” says on its official website. It’s the first time when software engineers could contribute to vaccine creation and even doing this at an elevated level of efficacity. The company will also develop vaccines for the veterinary area, as an example conducting research against the African Swine Fever. has been selected to be part of of KQ Labs, an accelerator programme at the Francis Crick Institute which helps companies to receive further support such as investments from government grants, venture capital as well as from other European resources.